AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11351143 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg b.i.d.
Number of subjects: 277
Study 11351143 — intervention group
Group type: EXPERIMENTAL
Intervention: Both medications
Number of subjects: 277
Study 9039219 — intervention group
Group type: EXPERIMENTAL
Intervention: retinyl palmitate (200,000 IU per week for 1 year)
Number of subjects: 106
Study 9039219 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 106
Study 1565812 — intervention group
Group type: EXPERIMENTAL
Intervention: E2H9R9 regimen (ethambutol, isoniazid, rifampicin, pyrazinamide for 9 months)
Number of subjects: 199
Study 1565812 — intervention group
Group type: EXPERIMENTAL
Intervention: Z2H9R9 regimen (ethambutol, isoniazid, rifampicin, pyrazinamide for 9 months)
Number of subjects: 199
Study 1565812 — intervention group
Group type: EXPERIMENTAL
Intervention: Z2H6R6 regimen (ethambutol, isoniazid, rifampicin, pyrazinamide for 6 months)
Number of subjects: 199
Study 1565812 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 199
Study 3909754 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 60
Study 3909754 — intervention group
Group type: COMPARATOR
Intervention: meglumine iothalamate
Number of subjects: 60
Study 30145365 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma PUFA levels (total, omega-3, omega-6)
Number of subjects: 0
Study 30145365 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary PUFA intake (omega-6)
Number of subjects: 0
Study 30145365 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined effects of antenatal vitamin D and early childhood PUFA
Number of subjects: 0
Study 28657825 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (12-week training regimen)
Number of subjects: 37
Study 28657825 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 37
Study 26973167 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol administration 40 min before extinction memory retrieval
Number of subjects: 0
Study 26973167 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration 40 min before extinction memory retrieval
Number of subjects: 0
Study 26973167 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol administration
Number of subjects: 0
Study 25226948 — intervention group
Group type: EXPERIMENTAL
Intervention: Four point weight bearing reduction system with a two‐belt treadmill, 40 minutes per day, 3 days per week for 4 weeks
Number of subjects: 20
Study 22246479 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 85
Study 22246479 — intervention group
Group type: COMPARATOR
Intervention: Control group (no HRT)
Number of subjects: 85
Study 20844543 — intervention group
Group type: EXPERIMENTAL
Intervention: Efonidipine-based regimen in strict-treatment group (target systolic BP <140 mm Hg)
Number of subjects: 4418
Study 20844543 — intervention group
Group type: EXPERIMENTAL
Intervention: Efonidipine-based regimen in mild-treatment group (target systolic BP 140 to <160 mm Hg)
Number of subjects: 4418
Study 20844543 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with baseline eGFR <60 ml min⁻¹ per 1.73 m²
Number of subjects: 4418
Study 20844543 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with baseline eGFR ≥60 ml min⁻¹ per 1.73 m²
Number of subjects: 4418
Study 20844543 — intervention group
Group type: EXPERIMENTAL
Intervention: Decline in eGFR
Number of subjects: 4418
Study 20844543 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteinuria at study entry
Number of subjects: 4418
Study 20844543 — intervention group
Group type: EXPERIMENTAL
Intervention: Efonidipine-based regimens
Number of subjects: 4418
Study 17715031 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (loading dose of 0.5 mg/kg in 30 ml normal saline over 5 min followed by an infusion of 50 microg.kg(‐1).min(‐1) until the end of surgery)
Number of subjects: 40
Study 17715031 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (as above)
Number of subjects: 40
Study 17715031 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 40
Study 16042670 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin 1200 mg day(‐1) for 7 days
Number of subjects: 14
Study 16042670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 12358953 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% nitrous oxide in oxygen
Number of subjects: 46
Study 12358953 — intervention group
Group type: COMPARATOR
Intervention: 40% oxygen in air (control group)
Number of subjects: 46
Study 10421302 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin A supplementation
Number of subjects: 480
Study 10421302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 480
Study 7668901 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased total IgA RF in RA patients
Number of subjects: 58
Study 7668901 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased IgA1 RF in RA patients
Number of subjects: 58
Study 7668901 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased IgA2 RF in RA patients
Number of subjects: 58
Study 7668901 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased concentrations of IgA RF and subclasses in RA patients with extraarticular manifestations
Number of subjects: 58
Study 7668901 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased IgA RF subclasses in RA patients
Number of subjects: 58
Study 7668901 — intervention group
Group type: COMPARATOR
Intervention: Increased IgA RF in non-rheumatic individuals
Number of subjects: 58
Study 1761737 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil single doses of 100, 200, 400, 600, and 800 mg
Number of subjects: 0
Study 1761737 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil multiple doses of 100, 200, and 400 mg twice daily for 15 days
Number of subjects: 0
Study 1761737 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil (both single and multiple doses)
Number of subjects: 0
Study 6625958 — intervention group
Group type: EXPERIMENTAL
Intervention: Active hemodialysis
Number of subjects: 24
Study 6625958 — intervention group
Group type: COMPARATOR
Intervention: Sham hemodialysis
Number of subjects: 24
Study 30965389 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom-limited incremental cycle exercise test (Group A)
Number of subjects: 129
Study 30965389 — intervention group
Group type: COMPARATOR
Intervention: Resting on exercise bicycles (Group B)
Number of subjects: 129
Study 30965389 — intervention group
Group type: COMPARATOR
Intervention: Symptom-limited incremental cycle exercise test (Group C)
Number of subjects: 129
Study 29912978 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet)
Number of subjects: 6430
Study 26466136 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral resistance training (URT) on the dominant leg (DOM)
Number of subjects: 17
Study 26466136 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 17
Study 24564441 — intervention group
Group type: EXPERIMENTAL
Intervention: After Deployment, Adaptive Parenting Tools (ADAPT)
Number of subjects: 42
Study 22207676 — intervention group
Group type: EXPERIMENTAL
Intervention: Duffy null (C/C genotype)
Number of subjects: 132
Study 22207676 — intervention group
Group type: COMPARATOR
Intervention: C/T or T/T genotypes
Number of subjects: 132
Study 19204593 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic physical training (8 weeks)
Number of subjects: 14
Study 19204593 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute resistance exercise test (ARET)
Number of subjects: 14
Study 17217442 — intervention group
Group type: EXPERIMENTAL
Intervention: XL/MMF
Number of subjects: 638
Study 17217442 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC/MMF
Number of subjects: 638
Study 17217442 — intervention group
Group type: COMPARATOR
Intervention: CsA/MMF
Number of subjects: 638
Study 15889519 — intervention group
Group type: EXPERIMENTAL
Intervention: Huanglian Fire‐Purging Mixture
Number of subjects: 72
Study 15889519 — intervention group
Group type: COMPARATOR
Intervention: Niuhuang Bolus for Lowering Blood Pressure
Number of subjects: 72
Study 12364422 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene hydrochloride at 60 mg/d (group A)
Number of subjects: 100
Study 12364422 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 tablet/d; group B)
Number of subjects: 100
Study 9868651 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/(kg.d) liposomal amphotericin B (L‐AmB‐1)
Number of subjects: 87
Study 9868651 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/(kg.d) liposomal amphotericin B (L‐AmB‐4)
Number of subjects: 87
Study 8202100 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 0
Study 3293408 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation therapy
Number of subjects: 0
Study 3293408 — intervention group
Group type: EXPERIMENTAL
Intervention: Hygienic informational therapy
Number of subjects: 0
Study 3293408 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondrug therapy (blood pressure responders)
Number of subjects: 0
Study 3293408 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0
Study 3293408 — intervention group
Group type: COMPARATOR
Intervention: Hygienic therapy
Number of subjects: 0
Study 31902431 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVR
Number of subjects: 742
Study 31902431 — intervention group
Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 742
Study 31482337 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D/3D image fusion
Number of subjects: 32
Study 31482337 — intervention group
Group type: COMPARATOR
Intervention: 2D/3D image fusion
Number of subjects: 32
Study 28262280 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision making (SDM) approach
Number of subjects: 50
Study 25423327 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium oxide 800 mg daily
Number of subjects: 289
Study 25423327 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium oxide 1200 mg daily
Number of subjects: 289
Study 25423327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 289
Study 22980639 — intervention group
Group type: EXPERIMENTAL
Intervention: 350 μm fragmentation grids
Number of subjects: 160
Study 22980639 — intervention group
Group type: COMPARATOR
Intervention: 500 μm fragmentation grids
Number of subjects: 160
Study 20423926 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep extension (coached to increase sleep by at least 30-60 min/night)
Number of subjects: 150
Study 20423926 — intervention group
Group type: COMPARATOR
Intervention: Comparison Group (maintains baseline sleep duration)
Number of subjects: 150
Study 18663663 — intervention group
Group type: EXPERIMENTAL
Intervention: Serological biomarkers (pepsinogen I, pepsinogen II, gastrin-17, Helicobacter pylori antibodies)
Number of subjects: 1000
Study 18663663 — intervention group
Group type: EXPERIMENTAL
Intervention: Serological biomarkers in subgroups (normal stomachs, H. pylori non-atrophic gastritis, H. pylori-negative gastritis)
Number of subjects: 1000
Study 15741837 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute heavy resistance exercise protocol (AHREP) consisting of 6 sets of 10 repetition maximum parallel squats
Number of subjects: 19
Study 15741837 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute heavy resistance exercise protocol (AHREP)
Number of subjects: 19
Study 12658930 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine plus routine therapy
Number of subjects: 50
Study 12658930 — intervention group
Group type: COMPARATOR
Intervention: Routine therapy only
Number of subjects: 50
Study 14528544 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback about fat intake
Number of subjects: 118
Study 14528544 — intervention group
Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 118
Study 14528544 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback for high fat consumers
Number of subjects: 118
Study 7539890 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 674
Study 7539890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 674
Study 2346354 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of rifamycin SV
Number of subjects: 268
Study 2346354 — intervention group
Group type: COMPARATOR
Intervention: Iodinated polyvidone dermal solution
Number of subjects: 268
Study 400108 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aerosol (100 microgram four times daily)
Number of subjects: 32
Study 400108 — intervention group
Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 32
Study 31501226 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with youth-onset T2D
Number of subjects: 397
Study 31501226 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with cardiac autonomic dysfunction
Number of subjects: 397
Study 31501226 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher HbA1c over time
Number of subjects: 397
Study 30942963 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterpik® Water Flosser (WF) plus manual toothbrush
Number of subjects: 72
Study 30942963 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush (MT) alone
Number of subjects: 72
Study 27217114 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (paracetamol)
Number of subjects: 0
Study 27217114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24650118 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study 24650118 — intervention group
Group type: COMPARATOR
Intervention: Generic Clopidogrel
Number of subjects: 0
Study 23100417 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision threshold modulation
Number of subjects: 0
Study 23100417 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroimaging results
Number of subjects: 0
Study 20618675 — intervention group
Group type: EXPERIMENTAL
Intervention: Chair‐type training machine for the elderly, 60‐min sessions twice a week for 12 weeks
Number of subjects: 24
Study 20618675 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24
Study 18363672 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-based ribavirin dosing (800-1400 mg/day) and PEG-IFN alfa-2b 1.5 microg/kg/week
Number of subjects: 3000
Study 18363672 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-based ribavirin dosing (800-1400 mg/day) and PEG-IFN alfa-2b 1.0 microg/kg/week
Number of subjects: 3000
Study 18363672 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-IFN alfa-2a 180 microg/week plus ribavirin 1000-1200 mg/day
Number of subjects: 3000
Study 15742451 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management program
Number of subjects: 273
Study 15742451 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (Control)
Number of subjects: 273
Study 12451365 — intervention group
Group type: EXPERIMENTAL
Intervention: Alefacept 7.5 mg
Number of subjects: 553
Study 12451365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 553
Study 10519433 — intervention group
Group type: COMPARATOR
Intervention: Methylergometrine
Number of subjects: 200
Study 10519433 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 200
Study 7547094 — intervention group
Group type: EXPERIMENTAL
Intervention: tenidap 120 mg day-1
Number of subjects: 14
Study 7547094 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study 2254678 — intervention group
Group type: EXPERIMENTAL
Intervention: Gingkco Biloba Extract (Tanakan)
Number of subjects: 37
Study 2254678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 7195230 — intervention group
Group type: EXPERIMENTAL
Intervention: AR-L 115 BS, 0.7 mg/kg
Number of subjects: 0
Study 7195230 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine, 0.01 mg/kg
Number of subjects: 0
Study 7195230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30921340 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA prime (ADVAX) and Modified Vaccine Ankara (MVA) boost
Number of subjects: 0
Study 30921340 — intervention group
Group type: COMPARATOR
Intervention: Homologous prime-boost regimen
Number of subjects: 0
Study 28660370 — intervention group
Group type: EXPERIMENTAL
Intervention: Coverage restrictions in prescription drug plans
Number of subjects: 0
Study 28660370 — intervention group
Group type: COMPARATOR
Intervention: Formulary generosity in prescription drug plans
Number of subjects: 0
Study 25188815 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 44
Study 25188815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 25063041 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean red ginseng (KRG) 2.7 g per day for 2 weeks
Number of subjects: 22
Study 21849055 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care in combination with the particular tape technique
Number of subjects: 140
Study 21849055 — intervention group
Group type: COMPARATOR
Intervention: Usual care without the tape technique
Number of subjects: 140
Study 19403556 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized self-management workbook intervention based on self-efficacy principles, duration 14 weeks.
Number of subjects: 10
Study 18611341 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,208 mmol/L (9%) KCl infusion
Number of subjects: 128
Study 18611341 — intervention group
Group type: COMPARATOR
Intervention: 201 mmol/L (1.5%) potassium chloride infusion
Number of subjects: 128
Study 18611341 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 128
Study 16257627 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance learning programme with educational materials
Number of subjects: 187
Study 16257627 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving mailed clinical guidelines on LUTS
Number of subjects: 187
Study 12522323 — intervention group
Group type: COMPARATOR
Intervention: Orlistat
Number of subjects: 0
Study 12522323 — intervention group
Group type: COMPARATOR
Intervention: Sibutramine
Number of subjects: 0
Study 12522323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12522323 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 0
Study 9934752 — intervention group
Group type: EXPERIMENTAL
Intervention: FECOM
Number of subjects: 12
Study 9934752 — intervention group
Group type: COMPARATOR
Intervention: barium paste
Number of subjects: 12
Study 7652501 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem (1 g 8-hourly)
Number of subjects: 338
Study 7652501 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime (2 g 8-hourly)
Number of subjects: 338
Study 7652501 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 338
Study 7652501 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 338
Study 7652501 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem and Ceftazidime
Number of subjects: 338
Study 1978026 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG3 monoclonal antibody
Number of subjects: 12
Study 1978026 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG1 monoclonal antibody
Number of subjects: 12
Study 1978026 — intervention group
Group type: COMPARATOR
Intervention: Polyclonal anti-D
Number of subjects: 12
Study 679941 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant Resistance (CR)
Number of subjects: 36
Study 679941 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable Resistance (VR)
Number of subjects: 36
Study 679941 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 36
Study 31682266 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg oral CBD
Number of subjects: 6
Study 31682266 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaporized CBD
Number of subjects: 6
Study 31682266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31682266 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaporized CBD-dominant cannabis (100 mg CBD; 3.7 mg ∆9-THC)
Number of subjects: 6
Study 30840057 — intervention group
Group type: EXPERIMENTAL
Intervention: 270° posterior partial fundoplication (PF)
Number of subjects: 456
Study 30840057 — intervention group
Group type: COMPARATOR
Intervention: 360° Nissen total fundoplication (TF)
Number of subjects: 456
Study 28276290 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dietary energy density (ED) characterized by higher intake of extra virgin olive oil (EVOO) and nuts
Number of subjects: 4259
Study 28276290 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest quintiles of ED change
Number of subjects: 4259
Study 28276290 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quintile of ED change
Number of subjects: 4259
Study 28276290 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased intake of EVOO and nuts
Number of subjects: 4259
Study 28276290 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased intake of other oils, vegetable and fruit consumption
Number of subjects: 4259
Study 25338198 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-access online care
Number of subjects: 156
Study 25338198 — intervention group
Group type: COMPARATOR
Intervention: In-person care
Number of subjects: 156
Study 25338198 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 156
Study 23276124 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 344
Study 23276124 — intervention group
Group type: COMPARATOR
Intervention: Progressive Muscle Relaxation Training (PMRT)
Number of subjects: 344
Study 21358487 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent pain and stress self-management group intervention (PASS)
Number of subjects: 156
Study 21358487 — intervention group
Group type: COMPARATOR
Intervention: Individually administered physical therapy (IAPT)
Number of subjects: 156
Study 19671780 — intervention group
Group type: EXPERIMENTAL
Intervention: Frozen finger intervention using a water-filled ordinary rubber glove
Number of subjects: 100
Study 17201801 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement-dose recombinant methionyl human leptin (r-metHuLeptin) during 72-hour fasting
Number of subjects: 6